Received Jun 27, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV9 | HPV (GARDASIL 9) | MERCK & CO. INC. | UNK | — | — |
HCP noted that her appointment was after 12 months.; No additional AE; Information has been received from Business Partner/CRO on 25-Jun-2025. This spontaneous report was received from a/an Other health professional and refers to a(n) female patient of unknown age. The patient's medical history was not reported. The patient's concurrent conditions were not reported. Concomitant therapies were not reported. On an unknown date, the patient started therapy with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9), (lot # and expiration date were not reported). The patient started therapy with Human Papillomavirus 9-valent Vaccine, Recombinant (GARDASIL®9), for the treatment of Prophylaxis. On an unknown date, the patient experienced HCP noted that her appointment was after 12 months.. On an unknown date, the patient experienced No additional AE. At the reporting time, the outcome of HCP noted that her appointment was after 12 months. and No additional AE was unknown. The action taken with Human Papillomavirus 9-valent Vaccine, Recombinant was reported as not applicable.